Lemeur Y, Moesch C, Rince M, Aldigier JC, Lerouxrobert C
Potential nephrotoxicity of intravenous infusions of naftidrofuryl oxalate

Nephrol Dial Transplant (Sep) 10:1751-1755 1995

Naftidrofuryl oxalate (not available in the United States) is used to treat arteriosclerosis obliterans in the form of an intravenous infusion. This report describes ARF associated with hyperoxaluria in two patients treated with this compound. In a subsequent study, administration of 800 mg/day for 10 days resulted in large increased in serum and urinary oxalate levels. Crystalluria was noted. The authors suggest that extreme caution must be used when giving naftidrofuryl oxalate intravenously to avoid renal damage. (Daugirdas)

To go back use the BACK button on your browser.
Otherwise click on the desired link to this article below:
ARF etiology : Other drug-associated ARF